![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Forty-seven normogonadotropic men with idiopatic asthenozoospermic were divided at random: group I (N= 22) received placebo and group II (N= 25) received 1200 mg of pentoxifylline/day during 6 months. Semen analysis was performed basal and at 3 and 6 months of the study period. No statistical changes in serum hormone concentration were found, nor in volume, sperm counts, viability, and morphology before and after treatment. Sperm motility increased following pentoxifylline treatment after 3 and 6 months from 25.5 (21.0–30.0) to 35.5 (31.5–39.0) (p<. 00001) and to 42.0 (38.0–46.0) (p<. 00001), respectively. Although in the placebo control cases some changes were observed in the sperm motility, they were less significant. Furthermore, progressive motility only in grade A increased with pentoxifylline from 2.5 (0.0–6.0) to 12.0 (6.0–19.5) (p<. 001) at 3 months and to 22.5 (17.0–26.0) at 6 months (p<. 00001). In conclusion, pentoxifylline had an additional effect rather than placebo and was useful treatment in these cases of male factor infertility.
Key Words: